期刊论文详细信息
| Journal of Translational Medicine | |
| coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) | |
| Oral Presentation | |
| 关键词: Overall Survival; Metastatic Melanoma; Vemurafenib; Creatine Phosphokinase; BRAF Inhibitor; | |
| DOI : 10.1186/1479-5876-13-S1-O4 | |
| 来源: Springer | |
 PDF
|
|
【 摘 要 】
【 授权许可】
CC BY
© Ascierto et al; licensee BioMed Central Ltd. 2015
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202311102972569ZK.pdf | 242KB |  download |
878987797
028-85220240
